Comparison of three clinical rating scales in Friedreich ataxia (FRDA)

Katrin Bürk, MD 1 2 *, Ulrike Mälzig, MD 1, Stefanie Wolf, PhD 1, Suzette Heck, MD 3, Konstantinos Dimitriadis, MD 3, Tanja Schmitz-Hübsch, MD 4, Sascha Hering, MD 5, Tobias M. Lindig, MD 6, Verena Haug, MD 7, Dagmar Timmann, MD 8, Ingrid Degen, MD 9, Bernd Kruse, MD 10, Jan-Markus Dörr, MD 11, Susanne Ratzka, MD 1, Anja Ivo, MD 4, Ludger Schöls, MD 6, Sylvia Boesch, MD 5, Thomas Klockgether, MD 4, Thomas Klopstock, MD 3, Jörg B. Schulz, MD 1

1Department of Neurodegeneration and Restorative Research, Centers of Molecular Physiology of the Brain and Neurological Medicine, University of Göttingen, Göttingen, Germany 2Department of Neurology, University of Marburg, Marburg, Germany 3Department of Neurology, University of Munich, Munich, Germany 4Department of Neurology, University of Bonn, Bonn, Germany 5Department of Neurology, University of Innsbruck, Innsbruck, Austria 6Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany 7Department of Neuropediatrics, University of Freiburg, Freiburg, Germany 8Department of Neurology, University of Essen, Essen, Germany 9Department of Neuropediatrics, Sankt Elisabeth Krankenhaus, Neuwied, Germany 10Department of Neuropediatrics, University of Hamburg, Hamburg, Germany 11Department of Neurology, Helios-Klinikum, Berlin, Germany

email: Katrin Bürk (buerk@ngi.de)

^*Correspondence to Katrin Bürk, Department of Neurodegeneration and Restorative Research, Center of Molecular Physiology of the Brain and Center of Neurological Medicine, University of Göttingen, Waldweg 33, Göttingen D-37073, Germany

Keywords: Friedreich ataxia • clinical rating scales • validation • SARA • ICARS • FARS